- Home
- BMEA vs CLSD Comparison
BMEA vs CLSD Comparison
Compare BMEA & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- CLSD
- Stock Information
- Founded
- BMEA 2017
- CLSD 2011
- Country
- BMEA United States
- CLSD United States
- Employees
- BMEA N/A
- CLSD N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- CLSD Health Care
- Exchange
- BMEA Nasdaq
- CLSD Nasdaq
- Market Cap
- BMEA 65.8M
- CLSD 59.1M
- IPO Year
- BMEA 2021
- CLSD 2016
- Fundamental
- Price
- BMEA $1.81
- CLSD $0.84
- Analyst Decision
- BMEA Strong Buy
- CLSD Strong Buy
- Analyst Count
- BMEA 10
- CLSD 5
- Target Price
- BMEA $22.30
- CLSD $4.80
- AVG Volume (30 Days)
- BMEA 5.2M
- CLSD 435.5K
- Earning Date
- BMEA 07-30-2025
- CLSD 08-11-2025
- Dividend Yield
- BMEA N/A
- CLSD N/A
- EPS Growth
- BMEA N/A
- CLSD N/A
- EPS
- BMEA N/A
- CLSD N/A
- Revenue
- BMEA N/A
- CLSD $3,764,000.00
- Revenue This Year
- BMEA N/A
- CLSD $60.52
- Revenue Next Year
- BMEA N/A
- CLSD $88.28
- P/E Ratio
- BMEA N/A
- CLSD N/A
- Revenue Growth
- BMEA N/A
- CLSD N/A
- 52 Week Low
- BMEA $1.29
- CLSD $0.70
- 52 Week High
- BMEA $13.07
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- BMEA 44.35
- CLSD 56.38
- Support Level
- BMEA $2.24
- CLSD $0.78
- Resistance Level
- BMEA $3.08
- CLSD $0.82
- Average True Range (ATR)
- BMEA 0.40
- CLSD 0.04
- MACD
- BMEA -0.03
- CLSD 0.01
- Stochastic Oscillator
- BMEA 25.07
- CLSD 91.50
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.